Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 7;9:677541. doi: 10.3389/fbioe.2021.677541

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Vozel, Božič, Jeran, Jan, Pajnič, Pađen, Steiner, Kralj-Iglič and Battelino.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Treatment outcome and symptoms at follow-up. (A) COMQ-12 average sum scores (Vozel et al., 2020a); (B) CPTBCI focus area percentages; (C) Kaplan–Meier curve. 95% CIs are included in graphs (A,B). Graph (C) is based on the data of 9 of 11 (82%) patients treated with PVRP who were symptom-free after the fourth checkup of the trial. Cumulatively, 49% of patients from the PVRP group remained symptom-free for 12.7 months after the fourth checkup. COMQ-12: chronic otitis media questionnaire 12; CPTBCI: chronic postoperative temporal bone cavity inflammation; PVRP: platelet- and extracellular vesicle-rich plasma; *statistically significant difference between groups within checkup; #statistically significant difference between the first and second checkups in the PVRP group.